VistaGen Therapeutics' (VTGN) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• VistaGen Therapeutics has had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating ongoing concerns about the stock's performance.
• In contrast, other firms like Wall Street Zen and William Blair have issued more favorable ratings, with Wall Street Zen upgrading the stock to "hold" and William Blair maintaining an "outperform" rating.
• The company's recent quarterly earnings revealed a reported loss of ($0.47) per share, matching consensus estimates, while revenue slightly exceeded expectations at $0.24 million.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

A number of other research firms have also recently commented on VTGN. Wall Street Zen raised VistaGen Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. William Blair reissued an "outperform" rating on shares of VistaGen Therapeutics in a report on Tuesday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, VistaGen Therapeutics presently has an average rating of "Hold".

VistaGen Therapeutics Price Performance

NASDAQ VTGN traded down $0.09 during midday trading on Friday, hitting $4.07. The company had a trading volume of 397,431 shares, compared to its average volume of 535,816. The firm has a 50-day moving average price of $3.55 and a 200-day moving average price of $2.79. VistaGen Therapeutics has a twelve month low of $1.90 and a twelve month high of $4.52.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.22 million. As a group, equities analysts predict that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of institutional investors have recently made changes to their positions in VTGN. Bank of America Corp DE grew its position in shares of VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock valued at $62,000 after buying an additional 19,331 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of VistaGen Therapeutics during the 1st quarter valued at about $25,000. ADAR1 Capital Management LLC boosted its position in shares of VistaGen Therapeutics by 246.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company's stock valued at $1,052,000 after purchasing an additional 299,304 shares in the last quarter. AdvisorShares Investments LLC boosted its position in shares of VistaGen Therapeutics by 27.7% during the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company's stock valued at $406,000 after purchasing an additional 44,000 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of VistaGen Therapeutics during the 2nd quarter valued at about $69,000. Institutional investors own 78.39% of the company's stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.